Berlin Heals Holding AG Secures $5 Million to Enhance Heart Failure Treatment Approaches

Berlin Heals Holding AG Secures Over $5 Million Funding

Berlin Heals Holding AG, a promising MedTech company based in Switzerland, has successfully raised more than $5 million in funding aimed at transforming the approach to heart failure treatment. This significant investment will enhance their efforts to develop an innovative medical device designed to reverse cardiac remodeling and help patients recover from heart failure.

The company, which has made substantial strides since its inception in 2014, has focused on a groundbreaking treatment method that utilizes a device consisting of two electrodes connected to an implantable generator. This device delivers a constant microcurrent to the heart, which has been found to reduce inflammation and restore the heart’s function. After positive outcomes from the initial studies conducted over the past few years, including a First-In-Human study in 2019 and a successful Randomized Controlled Trial completed in 2024, the path was set for further advancements.

The newly acquired funding comes after a successful A1 fundraising round earlier in the year, allowing the company to progress its development and initiate a new study titled CMIC-III. This trial aims to evaluate the effectiveness of a less invasive implantation procedure in an outpatient cardiac catheterization lab setting. By using this method, the company intends to enhance patient recovery times and broaden access to this innovative therapy across a wider range of hospitals.

John Brumfield, the CEO of Berlin Heals Holding AG, expressed gratitude towards both existing and new investors. He stated, "We are grateful for the continued and long-term support from our internal investors and welcome our new investors to the journey. Over 10 years ago, we set off on a mission to reshape the heart failure market, and our early results put us on the path to make that vision a reality. This new funding round will help accelerate our development to bring this new treatment to the millions of heart failure patients around the world."

Co-founder Marko Bagaric further emphasized the company’s commitment to not just alleviating symptoms, but actively reversing the impacts of heart failure. He noted that the clinical outcomes obtained from their preliminary studies surpassed initial expectations. The shift toward outpatient procedures, avoiding invasive surgeries, is anticipated to significantly expand the potential patient demographic that can benefit from such innovative solutions.

The C-MIC device (Cardiac Microcurrent), central to Berlin Heals’ research and development, is currently under investigation and will be assessed by CE regulatory authorities for potential approval. Impressively, the system has already been granted Breakthrough Device Designation and selected for the Total Product Life Cycle Advisory Program (TAP) with the FDA, indicating the device's promise and the urgency for its development.

In conclusion, Berlin Heals Holding AG is not only poised at the forefront of heart failure treatment innovation through their less invasive techniques but also reflects a larger trend within the MedTech industry aimed at improving patient outcomes. With sustained investment and groundbreaking research, the company is excited about the future possibilities for patients living with heart failure.